Global Deferasirox Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
According to our (Global Info Research) latest study, the global Deferasirox market size was valued at USD 2808.8 million in 2022 and is forecast to a readjusted size of USD 3773.2 million by 2029 with a CAGR of 4.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
This report is a detailed and comprehensive analysis for global Deferasirox market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Deferasirox market size and forecasts, in consumption value ($ Million), sales quantity (M Tablets), and average selling prices (USD/Tablet), 2018-2029
Global Deferasirox market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Tablets), and average selling prices (USD/Tablet), 2018-2029
Global Deferasirox market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Tablets), and average selling prices (USD/Tablet), 2018-2029
Global Deferasirox market shares of main players, shipments in revenue ($ Million), sales quantity (M Tablets), and ASP (USD/Tablet), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Deferasirox
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Deferasirox market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Cipla, Natco Pharma and Sun Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Deferasirox market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
    500 mg/Tablet
    250 mg/Tablet
    125 mg/Tablet
    Others
Market segment by Application
    Transfusional Iron Overload
    NTDT Caused Iron Overload
Major players covered
    Novartis
    Cipla
    Natco Pharma
    Sun Pharma
Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Deferasirox product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Deferasirox, with price, sales, revenue and global market share of Deferasirox from 2018 to 2023.
Chapter 3, the Deferasirox competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Deferasirox breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Deferasirox market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Deferasirox.
Chapter 14 and 15, to describe Deferasirox sales channel, distributors, customers, research findings and conclusion.